FDA approve new drug for treatment-resistant TB

05:12 EDT 15 Aug 2019 | Pharmafile

The US FDA has approved BPaL, the TB Alliance’s treatment for drug-resistant tuberculosis (TB).

The US regulator gave the go-ahead to the TB Allliance’s Pretomanid Tablets as part of a three drug combo, as a treatment for highly treatment-resistant TB of the lungs.

“The threat of antimicrobial-resistant infections is a key challenge we face as a public health agency,” said FDA Principal Deputy Commissioner, Dr Amy Abernethy.

read more

Original Article: FDA approve new drug for treatment-resistant TB


More From BioPortfolio on "FDA approve new drug for treatment-resistant TB"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...